Skip to main navigation Skip to main content

Clin Mol Hepatol : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

3
results for

"Chao Xu"

Article category

Keywords

Publication year

"Chao Xu"

Letter to the Editor

Molecular stratification of hepatocellular carcinoma by metabolic-signaling pathways guides precision immunotherapy and TACE therapy
Binghua Li, Yanchao Xu, Yican Zhu, Yukun Zhang, Zijie Wu, Tianci Luo, Laizhu Zhang, Weiwei Hu, Decai Yu
Clin Mol Hepatol 2026;32(1):e16-e20.
Published online May 8, 2025
DOI: https://doi.org/10.3350/cmh.2025.0344

Citations

Citations to this article as recorded by  Crossref logo
  • Correspondence to letter to the editor on “Distinct tumor immune microenvironment modulation by anti-PD-1/PD-L1, VEGF, and CTLA-4 blockade provides a rationale for triplet therapy in hepatocellular carcinoma”
    Hideki Iwamoto, Hironori Koga, Takumi Kawaguchi
    Clinical and Molecular Hepatology.2026; 32(3): e424.     CrossRef
  • Integrative multi-omics landscape and diagnostic-therapeutic modelling of steatohepatitic hepatocellular carcinoma
    Laizhu Zhang, Chaobo Chen, Yanchao Xu, Yuchen Zhang, Huan Li, Jingyuan Wen, Yajing Yang, Yunzheng Li, Yican Zhu, Weiwei Zong, Yukun Zhang, Tianming Chen, Chu Qiao, Bo Ran, Jialin Gao, Bing Han, Yue Hu, Chun Xu, Jun Chen, Xiaoli Mai, Jun Chen, Donglin Liu,
    Gut.2026; : gutjnl-2026-339304.     CrossRef
  • The survival prognosis after adjuvant transcatheter arterial chemoembolization in primary liver cancer: Aretrospective study
    Zhangjun Chen, Chang Lin, Jie Zhang
    Current Problems in Surgery.2025; : 101811.     CrossRef
  • S100A9 promotes resistance to anti-PD-1 immunotherapy in hepatocellular carcinoma by degrading PARP1 and activating the STAT3/PD-L1 pathway
    Xianwei Zhou, Chu Qiao, Xuehui Chu, Yajing Yang, Haoran Man, Jingxin Liu, Yunzheng Li, Zhu Xu, Huan Li, Xiaodong Shan, Zaowu Lian, Yanjun Lu, Weihong Wang, Decai Yu, Xitai Sun, Binghua Li
    Cellular Oncology.2025; 48(5): 1433.     CrossRef
  • 6,817 View
  • 173 Download
  • 2 Web of Science
  • Crossref

Correspondence

Artificial intelligence, epidemiology, methodology, or others

  • 7,333 View
  • 54 Download

Original Article

Artificial intelligence, epidemiology, methodology, or others

Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets
Yingzhou Shi, Hang Dong, Shiwei Sun, Xiaoqin Wu, Jiansong Fang, Jianbo Zhao, Junming Han, Zongyue Li, Huixiao Wu, Luna Liu, Wanhong Wu, Yang Tian, Guandou Yuan, Xiude Fan, Chao Xu
Clin Mol Hepatol 2024;30(1):80-97.
Published online December 7, 2023
DOI: https://doi.org/10.3350/cmh.2023.0343
Background/Aims
To evaluate the causal correlation between complement components and non-viral liver diseases and their potential use as druggable targets.
Methods
We conducted Mendelian randomization (MR) to assess the causal role of circulating complements in the risk of non-viral liver diseases. A complement-centric protein interaction network was constructed to explore biological functions and identify potential therapeutic options.
Results
In the MR analysis, genetically predicted levels of complement C1q C chain (C1QC) were positively associated with the risk of autoimmune hepatitis (odds ratio 1.125, 95% confidence interval 1.018–1.244), while complement factor H-related protein 5 (CFHR5) was positively associated with the risk of primary sclerosing cholangitis (PSC;1.193, 1.048– 1.357). On the other hand, CFHR1 (0.621, 0.497–0.776) and CFHR2 (0.824, 0.703–0.965) were inversely associated with the risk of alcohol-related cirrhosis. There were also significant inverse associations between C8 gamma chain (C8G) and PSC (0.832, 0.707–0.979), as well as the risk of metabolic dysfunction-associated steatotic liver disease (1.167, 1.036–1.314). Additionally, C1S (0.111, 0.018–0.672), C7 (1.631, 1.190–2.236), and CFHR2 (1.279, 1.059–1.546) were significantly associated with the risk of hepatocellular carcinoma. Proteins from the complement regulatory networks and various liver diseaserelated proteins share common biological processes. Furthermore, potential therapeutic drugs for various liver diseases were identified through drug repurposing based on the complement regulatory network.
Conclusions
Our study suggests that certain complement components, including C1S, C1QC, CFHR1, CFHR2, CFHR5, C7, and C8G, might play a role in non-viral liver diseases and could be potential targets for drug development.

Citations

Citations to this article as recorded by  Crossref logo
  • Untargeted Proteomics Profiling of Liver and Plasma in Fed and Fasted Liver‐Specific Glycogen Storage Disease Type Ia (GSD Ia) Mice: Toward Potential Protein Biomarkers
    Ruiqi Xiao, Hilda I. de Vries, Candelas Gross‐Valle, Aycha Bleeker, Terry G. J. Derks, Barbara M. Bakker, Maaike H. Oosterveer, Justina C. Wolters
    Journal of Inherited Metabolic Disease.2026;[Epub]     CrossRef
  • Integrated Bulk and Spatial Proteomics of Castleman Disease: Molecular Signatures Across Subtypes and Compartmentalized Pathogenic Networks in Idiopathic Multicentric Castleman disease (iMCD)–Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis/Renal Dys
    Shuang Zheng, Yu Huang, Xinyi Huang, Shuqi Li, Wenhui Zhang, Zheng Yang, Qinghua Cao
    Modern Pathology.2026; 39(11): 101071.     CrossRef
  • Large‐Scale Plasma Proteomics Reveals Preclinical Biomarkers of Incident Severe Liver Disease
    Shuzhen Zhao, Chengnan Guo, Xin Zhang, Haili Wang, Yi Li, Jiayi Huang, Luojia Dai, Zhenqiu Liu, Tiejun Zhang
    PROTEOMICS – Clinical Applications.2026;[Epub]     CrossRef
  • КЛІНІКО-МОРФОЛОГІЧНІ АСПЕКТИ ПЕРВИННОГО НЕАЛКОГОЛЬНОГО СТЕАТОГЕПАТИТУ ЗА НАЯВНОСТІ КОМОРБІДНОЇ ПАТОЛОГІЇ ЖОВЧНОГО МІХУРА
    О. Ю. Фофанова, В. В. Феденько, З. Я. Гурик, Е. О. Кіндратів, І. Г. Лаб'як
    Art of Medicine.2025; : 113.     CrossRef
  • Immune activation contributes recovery following pulmonary impairments by silica nanoparticles
    Caixia Guo, Xinying Zhao, Yan Li, Donglei Wang, Hailin Xu, Songqing Lv, Xueyan Li, Yanbo Li
    Journal of Hazardous Materials.2025; 496: 139403.     CrossRef
  • Plasma complement proteins as biomarkers and therapeutic targets in chronic kidney disease: a Mendelian randomization analysis
    Yu-Peng Xu, Zheng-Qi Song, Ming-Li Chen, Yang-Li Fang, Hui-Di Zhang
    Renal Failure.2025;[Epub]     CrossRef
  • Tissue-specific isoform usage and gene expression revealed through RNA-seq and ATAC-seq in developing cattle
    Sarem F. Khilji, Shangqian Xie, Gabrielle M. Becker, Katie A. Shira, Morgan R. Stegemiller, Julia L. Woods, Janet E. Williams, Lauren E. Christensen, Denise E. Konetchy, Darren E. Hagen,, Gordon K. Murdoch, Stephanie D. McKay, Brenda M. Murdoch
    BMC Genomics.2025;[Epub]     CrossRef
  • Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization
    Mohammad Saeid Rezaee-Zavareh, Naomy Kim, Ju Dong Yang
    Clinical and Molecular Hepatology.2024; 30(2): 150.     CrossRef
  • Constructing a disulfidptosis-related prognostic signature of hepatocellular carcinoma based on single-cell sequencing and weighted co-expression network analysis
    Zelin Tian, Junbo Song, Jiang She, Weixiang He, Shanshan Guo, Bingchen Dong
    Apoptosis.2024; 29(9-10): 1632.     CrossRef
  • Hepatocyte nuclear factor 4α is a critical factor for the production of complement components in the liver
    Carlos Ichiro Kasano-Camones, Satomi Yokota, Maiko Ohashi, Noriaki Sakamoto, Daichi Ito, Yoshifumi Saito, Ryo Uchida, Kazumi Ninomiya, Yusuke Inoue
    In Vitro Cellular & Developmental Biology - Animal.2024; 60(10): 1174.     CrossRef
  • 14,022 View
  • 277 Download
  • 14 Web of Science
  • Crossref